Latest Content

Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma

May 7th 2021, 9:00pm

By Colleen Moretti

Article

Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.

You May Have Second Thoughts When Receiving a Cancer Diagnosis

May 7th 2021, 6:00pm

By Mike Hennessy, Sr.

Article

Luckily, obtaining a second opinion has become easier with advances in telehealth and other virtual technologies, which allow patients to share their medical records and test results with physicians and pathologists to potentially improve treatment plans.

Rage at the Sun

May 7th 2021, 4:00pm

By Robin Zimmerman

Article

A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.

Friday Frontline: A Two-Time Cancer Survivor Becomes the Oldest Living American, A Nurse Serves as a Surrogate for a Cancer Survivor, And More

May 7th 2021, 3:00pm

By Jamie Cesanek

Article

From a 114-year-old cancer survivor breaking records to an operating room nurse giving birth to a cancer survivor’s baby, here’s what’s happening in the cancer landscape this week.

Prolonging Recurrence-Free Survival With Keytruda Does Not Come at the Price of Reduced Quality of Life for Patients with Melanoma

May 7th 2021, 1:00pm

By Colleen Moretti

Article

Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.

Venclexta With a Hypomethylating Agent Shows Promise for Patients with Acute Myeloid Leukemia

May 6th 2021, 9:00pm

By Colleen Moretti

Article

Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.

FDA Committee Recommends Continuing Accelerated Approval Status of Tecentriq in Certain Patients with Metastatic Triple-Negative Breast Cancer

May 6th 2021, 6:00pm

By Ryan McDonald

Article

Members of an FDA committee voted in favor of Tecentriq plus Abraxane keeping its accelerated approval for the treatment of adults with unresectable, locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.

When Oncologists Retire, Their Patients Must Learn to Embrace Change

May 6th 2021, 4:00pm

By Kelly Irvin

Article

“We’re all blessed that there are so many dedicated, caring health care professionals willing to step in and fill the void when members of the team move or retire,” writes a patient with cancer. “We can never forget how tough a gig it is or say thank you enough.”

A Prostate Cancer Researcher’s Unique Perspective as A Cancer Survivor

May 6th 2021, 3:00pm

By Jamie Cesanek

Podcast

In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.

FDA Grants Keytruda-Lenvima Combo Priority Review for Treatment of Advanced Kidney Cancer and Endometrial Cancer

May 6th 2021, 1:52pm

By Ryan McDonald

Article

The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.

Nurse Finds ‘Silver Lining’ for Survivors of Cancer with Virtual Visits

May 6th 2021, 1:00pm

By Colleen Moretti

Article

Virtual visits during the COVID-19 pandemic improved satisfaction and convenience, as well as reduced stress and anxiety in veterans who have survived cancer.

FDA Panel Votes in Favor of Upholding Tecentriq’s Indication in First-Line Treatment of Bladder Cancer

May 5th 2021, 9:00pm

By Ryan McDonald

Article

FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

FDA Approves Keytruda for Use With Trastuzumab and Chemotherapy for Subtypes of Stomach Cancer

May 5th 2021, 6:58pm

By Darlene Dobkowski, MA

Article

Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.

Unhealthy Habits May Increase in Some Women After a Breast Cancer Diagnosis

May 5th 2021, 6:00pm

By Colleen Moretti

Article

Women who receive a breast cancer diagnosis were more likely to develop unhealthy behaviors one and two years after diagnosis, even if they were considered healthy at time of diagnosis.

How Blizzards and Cancer Are Similar

May 5th 2021, 4:00pm

By Jane Biehl Ph.D.

Article

A cancer survivor recalls how a book quote about a blizzard became a metaphor for her own experiences with cancer.